MedTrace Logo

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

NCT07517198 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-08

No results posted yet for this study

Summary

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Conditions

  • Solid Tumor
  • Small Cell Lung Cancer (SCLC)
  • High Grade Neuroendocrine Cancer
  • Small Cell Carcinomas of Non-lung Origin
  • Non-small Cell Lung Cancer (NSCLC)
  • Prostate Cancer
  • Ovarian Cancer
  • Renal Carcinoma (Clear and Non-clear Cell)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Hepatic Cancer
  • Gastric Cancer
  • Triple-negative Breast Cancer (TNBC)

Interventions

DRUG

EXS74539

Oral administration

Sponsors & Collaborators

  • Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2029-03-31
Completion
2029-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07517198 on ClinicalTrials.gov